


DelRicht Completes Enrollment as the *Single Site Network* in Recent COVID Study

Our Objectives

DelRicht Research was **exclusively selected** as the site network for a Phase 3b/4 COVID-19 booster trial. The trial aimed to recruit an adolescent and adult population, including participants aged ≥ 12 to < 65 and ≥ 65 years.

- **Enrollment Goal:** 832 participants across 5 sites
- **Patient Population:** Participants aged ≥ 12 to < 65 and ≥ 65
- **Enrollment Period:** 9 weeks

Study Start-Up Timelines



The Study

Client: Global Biopharma Leader

Trial: US-Based Phase 3b/4 COVID-19 Booster Vaccine Trial

Participating PIs

Dr. Robert Springer | Atlanta, GA

Dr. Sean Kerby | Gulfport, MS

Dr. Patrick Dennis | New Orleans, LA

Dr. Taylor Sanders | Baton Rouge, LA

Dr. Melita Tate | Tulsa, OK



Trial Challenges

Like many large, multi-site clinical trials, the study presented several operational and recruitment complexities that posed challenges to both enrollment and overall execution.

1

Risk Factor Exclusions

Higher exclusion rates, requiring participants to have **at least one common risk factor** (e.g., obesity, diabetes, heart/lung disease, or immunocompromised status), severely limited the eligible pool.

2

Adolescent Recruitment

Engaging teens and their caregivers proved more difficult than recruiting independent adult healthy volunteers. **Coordinating schedules was challenging as teens had to attend with a parent/guardian.**

3

Vaccine Sentiment

Patient **hesitancy, especially around the placebo-controlled design**, impacted recruitment and retention.

[Our Solutions \$\rightarrow\$](#)

Solutions Implemented

DelRicht applied proactive recruitment, collaboration, and operational problem-solving to support enrollment and maintain efficient study conduct.

1

Optimizing for Risk Factor Exclusions

Recruitment efficiency and eligible yield were improved via **high-volume prescreening, refined early prequalification, targeted outreach to chronic-condition populations, and referral programs**, helping offset high exclusion rates among participants aged 12–65.

2

Facilitating Adolescent Enrollment

Adolescent recruitment was strengthened through **caregiver compensation, targeted social media and community outreach, and a structured priority scheduling system** that reserved capacity for caregiver-dependent visits, reducing barriers and informing strategies for hard-to-reach populations.

3

Addressing Vaccine Hesitancy

DelRicht reduced participant and caregiver hesitancy through education-focused initiatives, including **community events, enhanced digital resources (web content/FAQs), extended 1-on-1 screening visits, and standardized staff communication** frameworks covering placebo and trial ethics.

Our Results

DelRicht achieved rapid start-up from **award to activation in 39 days**, with seamless sponsor/CRO coordination. All sites **screened and enrolled the first patient** on activation day. Across five sites, **832 participants** were enrolled, meeting **100% of the target goal**, including full adolescent enrollment, with **90.1%** average diary compliance, reflecting high-quality, reliable data.



832 Patients Enrolled



90.1% Avg Diary Compliance



100% of the Expected Enrollment Goal

Let's Discuss Your Next Vaccine Trial

DelRicht Research is ready to support your upcoming vaccine study with the experience, infrastructure, and speed you need to succeed. We have supported **two vaccine/flu FDA approvals, mRESVIA and Xofluza**, and our teams are built to deliver results from study start-up through closeout.

delrichtresearch.com/sponsors

